Home » Newsletters » BioWorld Science

BioWorld Science

July 31, 2006

View Archived Issues

The neuroprotective effects of iron chelation in AD

Restoration of Uch-L1 is beneficial for neuronal and behavioral deficits associated with AD

BTG reports on Q1 progress

Solvay and Eisai sign codevelopment agreement for SA-001 in Japan

Denufosol tetrasodium studied in phase III cystic fibrosis study

Phase III study evaluates higher dose of glatiramer acetate in RRMS

Fast track designation for rhC1INH in hereditary angioedema

U.K. NICE recommends targeted biological therapies for severe plaque psoriasis

KMI-574: a modified and improved BACE1 inhibitor

New compounds with potential activity in neurological disorders reported

Novel flavanone analogue exhibits potent antileukemia activity

New agents claimed for treatment of psychological disorders

New agents for diabetes imparted in recent patent literature

Gabapen approved in Japan for epilepsy

Genotropin approved in Japan for severe adult growth hormone deficiency

Selective CD28 blockade prevents acute graft rejection in a primate model of heart transplant

Conditional European approvals for Sutent

Characterization of new p38 kinase inhibitors by Pharmacopeia

duetact approved for type 2 diabetes

Astellas reports data on novel immunosuppressant PG-695, alone or in combination with tacrolimus

Famvir approved for recurrent genital herpes and cold sores

European CHMP issues negative opinion for Tarceva in advanced pancreatic cancer

Zapaq presents in vivo results of memapsin-2 immunization

Suboxone receives approval recommendation in Europe

European CHMP hands down positive opinion for Gardasil

Champix recommended for approval in Europe

Glivec receives positive CHMP opinion for rare cancers

Xolegel approved for seborrheic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...